|

Adalimumab Clinical Trials

7 actively recruiting trials across 4 locations

▲ +1 trial since June 2026

Also known as: Humira, Simlandi

Pipeline

Phase 2: 2Phase 3: 2Phase 4: 1Phase 1/2: 1

Top Sponsors

  • University of Nebraska1
  • Universita di Verona1
  • Tom Appleton1
  • Swiss Dermatology Network for Targeted Therapies1
  • NYU Langone Health1

Indications

  • Arthritis6
  • Rheumatoid Arthritis2
  • Rheumatic Disease1
  • New Onset1
  • Juvenile Psoriatic Arthritis1

Other3 trials

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
Phase 2
Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)
Phase 4
Swiss Dermatology Network of Targeted Therapies (SDNTT)

Little Rock, Arkansas1 trial

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

Arkansas Children's Hospital /ID# 258776

Phase 3

San Francisco, California1 trial

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

UCSF

Phase 1/2

Omaha, Nebraska1 trial

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

University of Nebraska Medical Center

Phase 3

New York, New York1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NYU Langone Health

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.